Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Status unconfirmed

Conditions studied: NSCLC Stage IV, NSCLC, Recurrent

In brief

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.

Key facts

Study ID: NCT04636775
Run by: Jun Zhang, MD, PhD
People needed: 46
Starts: 2020-07-29
Expected to finish: 2024-12-31
Last updated by the study team: 2023-12-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Must have tumor tissue biopsy-proven to be NSCLC
Must have a target lesion to evaluate treatment response
Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients
Will receive single agent anti-PD-1/PD-L1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional trial if they will be receiving single agent anti-PD-1/PD-L1

You may not qualify if…

Prior treatment with any forms of cancer immunotherapy
Not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement
Not English-speaking
Patients that are pregnant
Prisoners
Students and employees
Psychiatric illness/social situations that would limit compliance with study requirements

Where it is running

The University of Kansas Cancer Center (KUCC) — Fairway, Kansas, United States (enrolling)
The University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.